Abstract
Factor VII is a single-chain, vitamin K-dependent glycoprotein of molecular weight 47 000–50 0001–5. Its plasma concentration is about 250–700ng/ml (5–15nmol/L). The complex of the zymogen factor VII with tissue thromboplastin and Ca2+ has been proposed as an efficient activator of factor X7,8 Factor VII can be converted to the two-chain α-VIIa by hydrolysis of an Arg-Ile bond by factors Xa, IXa, XIIa or thrombin1,2,6,10 The coagulant activity of α-VIIa is 100-fold increased compared to single-chain factor VII8. Further cleavage of α-VIIa at the heavy chain destroys coagulant activity9. The complex of factor VII/VIIa with tissue factor also activates factor IX to IXa11,12. Some authors13,14 virtually deny any physiologically relevant enzymatic activity to the complex of tissue factor with non-activated factor VII. Their concept of extrinsic activation requires the presence of factor VIIa in trace amounts. Factor Xa will then be generated by the factor VIIa/tissue factor complex (and also by reactions of the intrinsic coagulation pathway) and activate the thromboplastin bound zymogen factor VII to VIIa. This potent amplification loop is subjected to complex regulation mechanisms15.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Broze GJ, Majerus PW Purification and properties of human coagulation factor VII. J Biol Chem 1980; 255: 1242–7.
Bajaj SP, Rapaport SI, Brown SF Isolation and chracterization of human factor VII. Activation of factor VII by factor Xa. J Biol Chem 1981; 256: 253–9.
Radcliffe R.D, Nermerson Y. The activation and control of factor VII by activated factor X and thrombin. J Biol Chem 1975; 250: 338–95.
Broze GJ, Majerus PW Human VII. Meth Enzymol 1982; 80: 228–34.
Fair DS Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 1983; 62: 784–91.
Masys D.R, Bajaj SP, Rapaport SI Activation of human factor VII by activated factors IX and X. J Biol Chem 1981; 256: 253–9.
Radcliffe R, Nernerson Y Activation and control of factor X and thrombin: Isolation and characterization of a high chain form of factor VII. J Biol Chem 1972; 250:388–95.
Bach R, Oberdick J, Nernerson Y. Immunoaffinity purification of bovine factor VII. Blood 1984; 63: 393–8.
Radcliffe R, Nermerson Y Mechanism of action of bovine factor VII: Products of cleavage by factor Xa. J Biol Chem 1976; 251: 4797–802.
Radcliffe RD, Bagdasarian A, Colman R, Nemerson Y. Activation of bovine factor VII by Hageman factor fragments. Blood 1977; 50: 611–17.
Jesty J, Morrison SA. The activation of factor IX by tissue factor-factor VII in a bovine plasma system lacking factor X. Thromb Res 1983; 32: 171–81.
Born VJJ, Reinalda-Poot JH, Cupers R, Bertina RM Extrinsic activation of human blood coagulation factors IX and X. Thromb Haemostas 1990; 63: 224–30.
Rao LVM, Rapaport SI, Bajaj SP Activation of human factor VII in the initiation of tissue factor-dependent coagulation. Blood 1986; 68: 685–91.
Rao LVM, Rapaport SI Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687–91.
Sanders NL, Bajaj SP, Zivelin A, Rapaport SI Inhibition of tissue factor/factor VII activity in plasma requires factor X and an additional plasma component. Blood 1985; 66: 204–12.
Bloom AL Inherited disorders of blood coagulation. In: Bloom A.L, Thomas DP, eds. Haemostasis and Thrombosis, 2nd ed. Edinburgh: Churchill Livingstone, 1987; 393–441.
Roberts HR, Foster PA Inherited disorders of prothrombin conversion. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis, 2nd ed. Philadelphia: Lippincott, 1987; 162–81.
Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050–4.
Meade TW Factor VII and ischaemic heart disease: epidemiological evidence. Haemostasis 1983; 13: 178–85.
Meade TW, Mellows S, Brozovic M, Miller SG, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson ID, Thomson SG Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533–7.
Meade TW The epidemiology of haemostatic and other variables in coronary artery disease. In: Verstraete M, Vermylen J, Lijnen HR, Amout J, eds. Thrombosis and haernostasis. Leuven University Press 1987; 37–60.
Miller GJ, Seghatchian MJ, Walter SJ, Howarth DJ, Thompson SG, Esnouf MP, Meade TW An association between the factor VII coagulant activity and thrombin activity induced by surface/cold exposure of normal human plasma. Br J Haematol 1986; 62: 379–84.
Scarabin PY, Bonithon-Kopp C, Bara L, Malmejac A, Guize L, Samama M Factor VII activation and menopausal status. Thromb Res 1990; 57: 227–34.
Dalaker K, Hjermann I, Prydz H A novel form of factor VII in plasma from men at risk for cardiovascular disease. Br J Haematol 1985; 61: 315–22.
Scarabin PY, Van Dreden P, Bonithon-Kop C, Orssaud G, Bara L, Conard J, Samama M Age related changes in factor VII activation in healthy women. Clin Sci 1988; 75: 341–3.
Hoffman C, Shak A, Sodums M, Hultin MB Factor VII activity state in coronary artery disease. J Lab Clin Med 1988; 111: 475–81.
Miller GJ, Walter SJ, Stirling Y, Thompson SG, Esnouf MP, Meade TW Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha Vila in hyperlipaemia, with possible implications for ischaemic heart disease. Br J Haematol 1985;59: 249–58.
Czendlik C, Lämmle B, Duckert F. Cold promoted activation and factor XII, prekallikrein and C1-inhibitor. Thromb Haemostas 1985; 53: 242–4.
Gjnnaess H Cold promoted activation of factor VII. Occurrence and relation to sex hormones and antifertility compounds. Gynaecol Invest 1973; 4: 61–72.
Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI Activation of human factor VII in plasma and purified systems. Roles of activated factor IX, kallikrein and activated factor XII. J Clin Invest 1979; 64: 1056–65.
Barrowcliffe TW, Curtis AD Principles of bioassay. In: Bloom AL, Thomas DP, eds. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone, 1987; 996–1004.
Finney DJ Statistical method in biological assay, 3rd ed. London: Charles Griffin, 1978.
Brandt JT, Triplett DA, Fair DS Characterization and comparison of immune-depleted and hereditary factor VII-deficient plasmas as substrate plasma for factor VII assays. Am J Clin Pathol 1986; 85: 583–9.
Takase T, Tuddenham EG, Chand S, Goodall AH Monoclonal antibodies to human factor VII: production ofimmunodepleted plasma for VII:C assays. J Clin Patho11988; 41: 342-5.
Triplett DA, Brandt JT, Batard MA, Dixon JL, Fair DS Hereditary factor VII deficiency, heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284–7.
Bertina RM, Orlando M, Tiedemann-Aderkamp GH Preparation of a human factor VII deficient plasma. Thromb Res 1978; 13: 537–41.
Mustard JF, Secord D, Hoeksema TD, Downie HG, Rowsell HC Canine factor VII deficiency. Br J Haematol 1962; 8: 4347–54.
Gamer R, Conning DM The assay of human factor VII by means of modified factor VII deficient dog plasma. Br J Haematol 1970; 18: 57–66.
Poller L, Thomson JM, Sear CHJ, Thomas W Identification of a congenital defect of factor VII in a colony of beagle dogs: The clinical use of the plasma. J Clin Pathol 1971; 24: 626–31.
Duckert F Analytische Methoden. In: Koller F, Duckert F, eds. Thrombose und Embolie. Stuttgart: Schattauer, 1983; 761–78.
Thomson JM, Poller L Factor VIII assay proficiency assessment: experience in the UK. Scand J Haematol 1984; 33 (Suppl. 41): 101–8.
Maas RL, Triplett DA, Tholen D Factor VIII assay proficiency assessment: experience in the USA. Scand J Haematol 1984; 33 (Suppl. 41); 109–20.
Thompson SG, Duckert F, Haverkate F, Thomson JM The measurement of haemostatic factors in the European laboratories: quality assessment for the multicentre ECAT Angina pectoris study. Thromb Haemostas 1989; 61: 301–6.
Seligsohn U, Osterud B, Rapaport SL Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978–88.
Boyer C, Wolf M, Rothschild C, Migand M, Arniral J, Mannucci P.M, Meyer D, Larrieu MJ An enzyme immunoassay (ELISA) for the quantitation of human factor VII. Thromb Haemostas 1986; 56: 250–5.
Takase T, Tuddenham EG, Chand S, Goodall AH Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII: Ag. J Clin Pathol 1988; 41: 337–41.
Tirindelli MC, Mariani G, Mazzucconi MG, Iacopino G, Carbonaro M, Ghirardini A, Motta M, Mandelli F Evaluation of factor VII antigen in factor VII congenital deficiencies with a new ELISA assay. Am J Hematol 1987; 26: 313–21.
Carvalho de Sousa J, Azevedo J, Soria C, Barros F, Ribeiro C, Parreira F, Caen JP Factor VII hyperactivity in acute myocardial thrombosis. A relation to the coagulation activation. Thromb Res 1988; 51: 165–73.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Marbet, G.A., Duckert, F. (1992). Factor VII clotting activity. In: Jespersen, J., Bertina, R.M., Haverkate, F. (eds) ECAT Assay Procedures A Manual of Laboratory Techniques. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-2992-3_7
Download citation
DOI: https://doi.org/10.1007/978-94-011-2992-3_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5330-3
Online ISBN: 978-94-011-2992-3
eBook Packages: Springer Book Archive